Stenabolic (SR9009) is a synthetic compound initially developed as a REV-ERB agonist, now showing promise against aggressive prostate cancer (PCS1). Unlike standard therapies, it selectively induces cytotoxicity in cancer cells while sparing normal prostate tissue. SR9009 inhibits proliferation, migration, and colony formation and promotes apoptosis through the LXRα/FOXM1 pathway, downregulating key genes driving PCS1 aggressiveness. Preclinical studies confirm tumor reduction and safety, highlighting SR9009 as a novel, targeted therapy for advanced prostate cancer.
Xu, H., Zhang, J., Zheng, X., Tan, P., Xiong, X., Yi, X., Yang, Y., Wang, Y., Liao, D., Li, H., Wei, Q., Ai, J. and Yang, L., 2022. SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBs. Cell Death & Disease.
Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.
For detailed information about Stenobolic by Driada Medical, consult with your doctor or healthcare professional.
Xu, H., Zhang, J., Zheng, X., Tan, P., Xiong, X., Yi, X., Yang, Y., Wang, Y., Liao, D., Li, H., Wei, Q., Ai, J. and Yang, L., 2022. SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBs. Cell Death & Disease.
Xu, H., Zhang, J., Zheng, X., Tan, P., Xiong, X., Yi, X., Yang, Y., Wang, Y., Liao, D., Li, H., Wei, Q., Ai, J. and Yang, L., 2022. SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBs. Cell Death & Disease.
Xu, H., Zhang, J., Zheng, X., Tan, P., Xiong, X., Yi, X., Yang, Y., Wang, Y., Liao, D., Li, H., Wei, Q., Ai, J. and Yang, L., 2022. SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBs. Cell Death & Disease.
Home
